Physician profile
Alexander Gapay
NPI 1942201777
$7,783.81
in general payments reported to CMS, 2019-2025
38 companies · $1,023 in 2025
The $1,023 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,142 · 2020: $521 · 2021: $1,320 · 2022: $1,130 · 2023: $1,506 · 2024: $1,140 · 2025: $1,023.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,593 · Education: $77.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,592.92 |
| Education | $77.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,343.09 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $879.41 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $751.90 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Amarin Pharma, INC. | $673.11 | 2019-2023 | |
| Novo Nordisk INC | $546.65 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $398.12 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $381.91 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Abbvie INC. | $330.65 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $321.97 | 2022-2025 | Xifaxan, Trulance |
| Pfizer INC. | $316.39 | 2019-2025 | |
| Esperion Therapeutics, INC. | $232.84 | 2021-2024 | Nexletol |
| Amgen INC. | $188.63 | 2019-2025 | Repatha, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $167.18 | 2022-2025 | |
| Exact Sciences Corporation | $136.44 | 2023-2025 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $126.99 | 2023-2024 | Camzyos, Eliquis |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Gapay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.